Oncology Billing That Protects Your Drug Margin and Cash Flow

Overlooked Denials in Oncology Billing

The Drugs You Buy Aren't Always Fully Paid Back

You pay for expensive infusion drugs up front, then wait to be reimbursed. When the amount given, the leftover discarded from a single-use vial, or the site where care was delivered isn't documented cleanly, the insurer pays back less than you spent - turning a treatment that should make money into one that quietly loses it.

Chair Time You Delivered Doesn't All Reach the Claim

Infusion and injection revenue is driven by how long the patient is in the chair and how many drugs are given in the visit. When the start-and-stop times and the full sequence of what was administered aren't captured, hours of care you actually provided never make it onto the bill.

High-Cost Regimens Get Delivered Before They're Approved

Biologics and immunotherapies need the insurer's sign-off before the patient is treated. Start therapy while the approval is still pending and the claim comes back denied - leaving you holding the cost of a drug you already infused with no way to bill for it.

Multi-Drug Visits Get Collapsed Into One Payment

When several drugs are given in a single visit, each should be paid on its own. If the visit isn't documented so the payer can see them as distinct services, they get bundled together and you're paid for one when you delivered several.

Radiation Planning Work Is Given Away for Free

A course of radiation is far more than the beam time - simulation, dose planning, and ongoing treatment management are all separately payable work. Practices that only bill the daily treatment leave the planning revenue, often the most valuable part of the episode, uncollected.

Research-Covered Care Billed to the Patient Becomes a Compliance Problem

In clinical trials, some services are paid by the study and some are billed to insurance - and the line between them is strict. Bill the wrong side of it and you're not looking at a simple correction, you're looking at a repayment demand and a compliance exposure.

How We Rebuild Oncology Revenue

Your Drug Costs Recovered in Full

We make sure every expensive drug you purchase is billed back accurately - the right amount given, the discarded portion accounted for, and the correct site of service - so the money you lay out on acquisition actually comes back.

• Full reimbursement on the drugs you buy and infuse
• Discarded-drug amounts captured, not written off
• Site-of-service billed for the best allowable payment
• Margin between what you pay and what you're paid protected

Every Hour in the Chair Captured

We document the full length of each infusion and every drug delivered in the visit, so the chair time and supportive care you actually provided all reach the claim instead of being left off.

• Infusion time billed to the full duration delivered
• Every drug in a multi-drug visit paid separately
• Hydration and supportive care included, not overlooked
• Injections and supportive services fully accounted for

Approvals Cleared Before You Treat

A dedicated team secures authorization for high-cost biologics, immunotherapies, and targeted regimens before the patient is in the chair - so you never infuse an expensive drug you can't get paid for.

• Approvals in hand before treatment begins
• Strong medical-necessity documentation up front
• Physician-to-physician review support when payers push back
• Fewer treatment delays for your patients

Radiation Episodes Billed End to End

For radiation oncology, we bill the full arc of the episode - planning, simulation, dose work, and ongoing treatment management - so the most valuable part of the course is collected, not given away.

• Planning and simulation work billed as its own revenue
• Professional and facility portions both captured
• Ongoing treatment management collected across the course
• No high-value planning work left off the claim

Dedicated Oncology Billing Services

Chemotherapy Administration

Expert billing for IV push, infusion, intra-arterial, and subcutaneous chemotherapy with proper sequencing and drug billing.

• IV chemotherapy infusion
• IV push administration
• Concurrent therapy
• Sequential drug administration

Immunotherapy & Biologics

Specialized billing for immunotherapy infusions, biologic medications, and targeted cancer therapies with specialty-drug billing expertise.

• Immunotherapy infusions
• Monoclonal antibodies
• CAR-T cell therapy
• Targeted biologic drugs

Radiation Oncology

End-to-end billing for radiation therapy planning, simulation, dosimetry, treatment delivery, and management services.

• Radiation treatment planning
• Radiation simulation
• Dosimetry calculations
• Treatment management

Oncology Drug Billing

Accurate billing for chemotherapy drugs, supportive medications, and oncology supplies with proper drug and supply billing.

• Specialty drug billing
• Supportive care drugs
• Antiemetic administration
• Drug wastage documentation

Frequently Asked Questions

What makes oncology billing uniquely complex?

Oncology is among the most complex specialties to bill: (1) Drug administration has strict timing rules - the first hour of the first infused drug, each additional hour, and each additional sequential drug are billed differently, and mis-timing leads to systematic underpayment; (2) the drugs themselves are billed by precise units, where a single dose can translate into hundreds of billable units, so a unit-conversion error is a large dollar error; (3) the buy-and-bill model means the practice purchases expensive drugs and bills payers afterward, creating major cash-flow and inventory exposure; (4) radiation therapy carries layered treatment-planning, daily-delivery, and weekly-management billing; (5) clinical trial billing requires separating what the study covers from what's billable to insurance; and (6) molecular and genetic testing carries heavy prior-authorization and coverage requirements. Any one of these, done loosely, turns a profitable service into a loss.

How are injectable and infusion oncology drugs billed?

Billing infused and injected oncology drugs is where a large share of a practice's revenue - and its risk - lives, because the payment turns on precise dose-to-billing-unit math rather than a simple per-visit charge. Each drug is reimbursed in defined units (for example, per milligram or per 10 milligrams), so the milligrams actually administered must be converted to the correct number of billable units; an error here quietly under- or over-bills every infusion. Partially used single-use vials must have the discarded portion documented and reported as drug waste so the practice is paid for the full vial it purchased. Many payers also require the drug's National Drug Code, lot number, and manufacturer on the claim. Reimbursement is tied to Medicare's average sales price plus a percentage add-on, and because that price is refreshed every quarter, expected payment shifts throughout the year. Biosimilars are reimbursed on their own average-sales-price basis rather than the reference product's. Because oncology practices buy these drugs before they bill for them, any of these errors turns directly into a cash-flow loss.

What prior authorizations are required for cancer treatment?

Oncology prior authorization requirements are extensive: **Chemotherapy Regimens:** Most commercial payers require prior auth for all chemotherapy protocols, with documentation of cancer type, stage, biomarker results, and NCCN guideline-concordant treatment selection. **Immunotherapy:** PD-1/PD-L1 inhibitors, CAR-T cell therapy, and other biologics require prior auth with companion diagnostic results. **Radiation Therapy:** Treatment planning and delivery often require prior auth with tumor board documentation and treatment rationale. **Molecular/Genetic Testing:** Comprehensive genomic profiling (Foundation Medicine, Tempus, Guardant) requires prior auth with documentation of how results will impact treatment decisions. **PET/CT Scans:** Typically require prior auth for staging and restaging with specific ICD-10 codes. **Clinical Trial Services:** Qualifying services are covered by insurance, but non-qualifying trial-specific services are sponsor responsibility - requires careful separation. **Timeline:** Submit 5-10 business days before treatment start; urgent/emergent cases may qualify for expedited review.

Why are oncology claims denied and what are the financial impacts?

Oncology claim denials are financially devastating due to high drug costs: **Drug Unit Calculation Errors:** Incorrect drug-unit counts are the most common error - billing 200 units instead of 20 (or vice versa) for a $15,000 drug. **Medical Necessity:** Off-label drug use without NCCN Compendium support, or treatment continuation without documented response assessment. **Prior Authorization Failure:** Expired or missing auth for chemotherapy regimens - a single denied infusion can mean $5,000-$50,000 in unrecoverable revenue. **Sequestration/Payment Adjustments:** Medicare sequestration reduces payments by 2%, and ASP-based reimbursement may fall below acquisition cost for some drugs. **Timely Filing:** Complex oncology claims with multiple drugs and services often miss filing deadlines during appeals - track every claim from day one. **Buy-and-Bill Cash Flow Risk:** When a $20,000 drug claim is denied, the practice has already purchased and administered the drug - the financial exposure is immediate and significant.

What Drives Oncology Revenue

The Economics of Buying and Billing Your Own Drugs

When your practice buys infusion drugs and administers them in-house, your profit is the gap between what you pay for the drug and what the insurer pays you back. That gap only survives if the billing is airtight. If the exact amount given to the patient isn't documented, if the portion left over and discarded from a single-use vial isn't accounted for, or if the location where care was delivered is recorded in a way that pays less, you end up reimbursed for less than the drug cost you - and an expensive infusion becomes a money-loser instead of a margin.

• Your margin is the spread between drug acquisition cost and reimbursement - thin, and easy to erase
• The full amount administered must be documented so you're paid for everything given
• Leftover drug discarded from a single-use vial is separately reimbursable - capture it, don't absorb it
• Where care is delivered changes what the drug pays - the setting has to be recorded correctly

Immunotherapy and Targeted Therapy: Two Payment Paths

Cancer care has shifted heavily toward immunotherapies and targeted therapies, and how you get paid depends on how the drug is delivered. Drugs you infuse in your office are reimbursed under the patient's medical benefit - you buy them, you bill them, and the margin flows to you. Oral targeted agents the patient fills at a pharmacy are paid under their drug benefit and run through a specialty pharmacy, so they never touch your billing but do require coordination so the patient can actually start therapy. Knowing which path each drug takes prevents denials and keeps patients from being blindsided by their share of the cost.

• Infused agents are billed by your practice under the medical benefit - the revenue and margin are yours
• Oral agents run through a specialty pharmacy under the drug benefit - coordination, not a claim you bill
• Certain advanced cell therapies are hospital-delivered only and fall outside office billing
• Some drugs require enrollment in a safety program before they can be dispensed or given

Getting Paid for Coordinating Complex Cancer Care

Medicare and commercial payers increasingly reward oncology practices for managing the whole patient, not just delivering treatment. Programs tied to value-based cancer care pay a recurring monthly amount for coordinating each patient's care and can share savings back to the practice when total treatment costs stay under target. Earning that money depends on documenting the coordination work you already do - monthly check-ins, treatment summaries, survivorship planning, and patient navigation. Even outside a formal program, quality reporting directly moves your Medicare payment up or down, so the documentation is money either way.

• Recurring monthly care-coordination payments reward the management work you already provide
• Documenting monthly touchpoints and treatment summaries is what unlocks that revenue
• Survivorship planning after treatment counts toward quality credit
• Quality reporting swings your Medicare payments up or down - the paperwork pays

One Primary Service Per Infusion Day

A treatment day in the infusion suite produces a stack of billable work: the main chemotherapy agent, additional drugs given in sequence, pre-medications, and hydration. Payer rules price that stack through a strict ordering with one iron rule: only one service on the day counts as the primary administration, and everything else is billed relative to it.

Claim two primaries and the payer's edits reject the visit; forget the secondary drugs and you silently underbill work you documented and delivered.

What the nursing chart controls

The nursing chart is effectively the billing system here. When recorded start and stop times, drug sequence, and volumes line up with the ordering rules, the practice collects everything the day allows. When they don't, additional-hour charges can't be defended and hydration billed by default becomes an audit pattern rather than revenue.

• Only one administration service on each treatment day counts as primary; the rest bill in relation to it
• Claiming two primaries triggers automatic rejection; dropping secondary drugs quietly underbills the visit
• Additional infusion hours are only as defensible as the documented start and stop times behind them
• Hydration is payable when it is a distinct, necessary service, not when it is billed reflexively on every visit

Reconciling Doses, Vials, and Wastage Before the Claim Goes Out

Cancer drug doses are calculated from the patient's weight or body surface area, so they rarely match vial sizes exactly, and the billed quantity rarely matches milligrams one-to-one. Every drug claim is therefore an arithmetic exercise: the dose administered, converted into the payer's billing quantity, reconciled against the vials actually opened.

Get the conversion wrong in one direction and you donate most of the drug; get it wrong in the other and you overbill straight into a payer audit.

Reporting discarded drug

Layered on top is the wastage requirement - claims for drugs from single-use vials must either report the discarded amount on its own payable line or attest that nothing was discarded. Reported wastage is real revenue. Quantities that cannot be reconciled against actual vial sizes are precisely what payer integrity software is built to flag.

• Weight-based dosing means billed quantities must be converted and reconciled against vials opened, on every claim
• A conversion error either donates drug you paid for or overbills into an audit
• Discarded drug from single-use vials must be reported on its own line or attested as zero; reported wastage is payable
• Quantity totals that don't reconcile against real vial sizes are a primary audit trigger

When the Regimen Changes, the Approval Has to Change With It

Prior authorization in oncology is not one hurdle at the start of treatment; the approval is tied to the specific diagnosis, line of therapy, and often the exact dose and cycle count. Dose reductions, agent swaps, and added drugs are clinically routine, and each one is administratively dangerous: if the change isn't reflected in the authorization before the next visit, the practice infuses an expensive drug against an approval that no longer matches, and the claim denies after the cost is already sunk.

The protection is an authorization ledger reconciled against the treatment calendar, so every planned infusion is checked against a currently valid approval.

Patients on clinical trials

The same discipline applies to patients on clinical trials, where routine care bills to insurance with the required study designations while sponsor-paid items are carved out - mixing the two creates repayment exposure in one direction and donated care in the other.

• Approvals are tied to the specific regimen, dose, and cycle count, not just the diagnosis
• Every mid-course dose reduction or agent swap must reach the payer before the next infusion
• An authorization ledger checked against the treatment calendar is drug-inventory protection, not paperwork
• Trial patients' claims must separate insurance-billable routine care from sponsor-paid items on every visit

Navigating Payers on Oncology Reimbursement

Medicare Part B

• Medicare sets what it pays for your infusion drugs off a published benchmark that changes every quarter - if you aren't tracking it, you may be billing below what you're owed
• Anti-nausea and supportive drugs given alongside treatment are covered - bill them, don't absorb the cost
• Oral cancer drugs are paid under a different benefit and often at a worse rate for the patient - set expectations early to avoid abandoned therapy
• Care planning and advance-directive documentation feeds quality scoring that affects your payments

Medicaid

• Approval requirements for cancer treatment vary widely from state to state - verify before you treat, not after
• Children's coverage is broad, including advanced therapies for certain cancers
• Standard generic drugs are usually covered, but biologics almost always need approval first
• Managed Medicaid networks can be narrow - confirm you're in-network before starting a patient

Commercial Payers

• Nearly every chemotherapy and biologic regimen needs approval with clinical justification before treatment
• Citing recognized national cancer treatment guidelines in the request speeds approvals
• Off-label and compassionate-use requests need supporting evidence attached to get through
• Some plans only pay at full rates if you're in their preferred cancer network or center-of-excellence program
• Some plans force certain drugs through their own specialty pharmacy instead of your inventory, removing both the cost and the margin from your practice - know which regimens this applies to before treatment is scheduled
• Negotiated drug rates vary enough by plan that each major regimen deserves its own acquisition-versus-reimbursement picture; a regimen that loses money should be a deliberate decision, not a surprise

Radiation Oncology

• A radiation course has both a physician side and a facility side - both need to be billed to collect the full episode
• Planning and delivery work is paid as a package - bill it as intended so nothing is denied as duplicative
• Advanced modalities like proton therapy typically require payer review and approval before treatment
• Palliative radiation needs the patient's symptoms and expected course documented to be paid

Related Billing Resources

• Internal Medicine Billing
• Interventional Radiology Billing
• Laboratory Billing Services
• Prior Authorization Services
• Denial Management Services
• Laboratory & Pathology Billing
• Pharmacy Billing

Related Resources

• Interventional Radiology Billing - Related image-guided tumor and biopsy procedure billing.
• Internal Medicine Billing - Related infusion and complex adult care billing.
• Prior Authorization - Navigate complex cancer treatment authorizations.